Better outlook, still a messy spin-off
- Q1 2026 organic sales grew 2.1%, but reported revenue fell 3.0% after the Purification and Filtration sale.
- Management now expects adjusted EPS to land at the high end of its $6.40 to $6.60 full-year range.
- Dental Solutions and Health Information Systems are the cleanest growth stories, with Q1 organic growth of 3.4% and 4.7%.
- MedSurg is the biggest segment, and its Q1 operating margin fell to 13.1% from 17.8% because of tariffs and inflation.
- The big outside risk is 3M supply dependence, with about $3 billion of 2025 revenue tied to materials where 3M is the sole source.
Guidance helps, MedSurg still hurts
Solventum is in a better place than it was right after the 3M spin-off. It sold the Purification and Filtration business in 2025 for about $4 billion and used much of the cash to pay down debt. That gave the company room to start a $1 billion share buyback program, with $67 million bought back in Q1 2026.
The bull case is simple. The company is growing where it wants to grow, especially Dental Solutions and Health Information Systems. In Q1 2026, those segments posted 3.4% and 4.7% organic growth, which means growth before currency, acquisitions, and divestitures. Their margins also improved, which suggests the cost program is working in those areas.
The bear case is also clear. MedSurg is the largest segment, and its operating margin fell to 13.1% in Q1 2026 from 17.8% a year earlier. Management blamed tariffs and inflation. The latest call eased some concern because management said full-year adjusted EPS should be at the high end of the $6.40 to $6.60 range, but investors still need proof that MedSurg margins can recover.
Finn's view is balanced. Solventum has real products, strong niches, and a better balance sheet. It also has a low-growth profile, spin-off cleanup costs, and a serious 3M supply risk. The stock needs cleaner cash flow and proof that the biggest segment can earn better margins.
Medical products with software upside
Solventum makes money by selling medical supplies, dental products, and healthcare software to hospitals, clinics, dentists, and health systems. MedSurg includes wound care and I.V. site products. Dental Solutions sells items like restorative cements and orthodontic products. Health Information Systems sells software that helps hospitals code care, manage records, and improve clinician work.
The company is trying to grow through new products, sharper sales focus, and small acquisitions. The Acera Surgical deal added regenerative wound care to MedSurg. Management has said tuck-in deals will usually be below $1 billion, which keeps the focus on smaller targets in markets Solventum already knows.
The main profit lever is the multi-year Transform for the Future program. That means cutting costs, simplifying operations, and moving spending toward better growth areas. The tension is that the program now has to do two jobs at once: fund growth and offset tariffs and inflation, especially in MedSurg.
Cash flow is the other test. Q1 2026 operating cash flow was negative because of separation-related payments to 3M. The model should look better as Solventum exits 3M transition services, but the company has to show that on the cash flow statement.
What Solventum sells
Advanced wound care
This includes single-use negative pressure wound therapy and other products used to treat wounds. Acera Surgical adds regenerative wound care to this part of MedSurg.
I.V. site management
These products help secure and protect I.V. sites in hospitals and clinics. Q1 MedSurg growth was helped by volume growth in I.V. site management.
Infection prevention and surgical solutions
This is part of the MedSurg base. It gives Solventum a large hospital footprint, but it also sits in the segment now facing tariff and inflation pressure.
Dental restorative and prevention
These products include restorative and prevention solutions used by dental offices. This area led Dental Solutions growth in Q1 2026.
Traditional orthodontics and dental cements
Solventum sells orthodontic products and dental composites and cements. Some dental materials depend on supply from 3M, which makes this a key area to watch.
360 Encompass and performance software
Health Information Systems includes Solventum 360 Encompass and performance management tools. This segment had the best Q1 operating margin at 38.1%.
MedSurg still dominates
Shares use Q1 2026 net sales from the Form 10-Q: MedSurg $1,234 million, Dental Solutions $354 million, Health Information Systems $342 million, All Other $76 million, and total company sales of $2,007 million. MedSurg is the largest profit risk because its margin fell sharply in the same quarter.
What could break the story
MedSurg margin recovery fails
High impact · Medium oddsMedSurg is Solventum's largest segment by Q1 2026 sales. Its operating margin fell to 13.1% from 17.8% a year earlier because of tariffs and inflation. If pricing and cost cuts do not offset those costs, the high-end EPS outlook becomes harder to reach.
3M sole-source supply problem
High impact · Medium oddsSolventum says 3M is the sole source for certain materials used in products that accounted for about $3 billion of fiscal 2025 revenue. That includes a proprietary 3M process tied to products that generated about $2 billion of revenue. A supply disruption or bad pricing reset could hit sales and margins.
Spin-off cash drag lasts too long
Medium impact · Medium oddsOperating cash flow was negative in Q1 2026, hurt by separation-related payments to 3M. These costs should fade as Solventum exits transition services and its own systems are ready. If they last longer, debt paydown and buybacks become less attractive.
Transform for the Future misses targets
Medium impact · Medium oddsThe restructuring program is meant to cut costs and fund growth. It is already helping Dental Solutions and Health Information Systems margins. The risk is that savings arrive late, cost more than expected, or fail to cover MedSurg inflation.
PFAS liabilities move back into focus
Medium impact · Low oddsSolventum is generally responsible for PFAS-related liabilities from its own business after the spin-off. Some 3M indemnification for certain products only extended through the end of 2025. A new claim or broader legal ruling could raise the cost of being a former 3M business.
In one breath
What does Solventum do?
Solventum sells healthcare products and software. Its main areas are MedSurg, Dental Solutions, and Health Information Systems.
Why did Solventum spin off from 3M?
Solventum became a separate public company so the healthcare business could run with its own strategy and capital plan. The separation also created costs, system changes, and supply ties that still matter.
Is Solventum growing?
Yes, but not quickly. Q1 2026 organic sales grew 2.1%, with stronger growth in Dental Solutions and Health Information Systems than in MedSurg.
What is the biggest risk for Solventum stock?
The biggest watch item is MedSurg margin recovery. The largest outside risk is the supply dependence on 3M for materials tied to about $3 billion of fiscal 2025 revenue.